Horizon Announces Expansion and Relocation of U.S. Corporate Headquarters
News Oct 09, 2015
Horizon Pharma plc has announced that it is expanding and relocating its U.S. corporate headquarters from Deerfield, Ill. to Lake Forest, Ill., with the signing of a long-term sublease for its new office space at 150 South Saunders Road.
The new office space is approximately triple the size of the current U.S. headquarters and can accommodate nearly 600 employees. Horizon Pharma will occupy the first through fourth floors of the 160,000-square-foot building. The expansion and relocation is expected to be completed in January 2016.
"Horizon has come a long way in eight years -- from one employee working in a coffee shop -- to more than 700 global employees," said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma plc. "In the last year alone, we have added nearly 100 employees in our U.S. headquarters and have experienced tremendous growth in the business overall. With this progress, as well as planning for future expansion, we needed to increase our physical space. Our new U.S. headquarters will provide us room to continue on this growth trajectory, and ultimately, to serve more patients."
"The City of Lake Forest is pleased to welcome Horizon Pharma, a rapidly growing biopharmaceutical company, and its current and future employees to the community," said Mayor Donald Schoenheider. "Horizon Pharma joins other corporate headquarters in the Route 60 Corridor, at the western gateway to the City. As a community, we look forward to building a long-term relationship with Horizon Pharma. We are excited to see ongoing interest and enhancement of the City's premier corporate office area. Lake Forest is a great place to do business."
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE